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1. Introduction 
1.1 Historical overview 
Renal transplantation remains the most effective treatment modality for end-stage renal 
disease. The initial results with renal transplantation were plagued with significant 
perioperative morbidity and high rates of immunological events. At the time, the transplant 
physician’s armamentarium consisted of glucocorticoids and azathioprine. As modifications 
and improvements in surgical technique reduced morbidity, immunological events 
remained formidable foes to the transplant physician. Significant efforts were undertaken to 
elucidate the components and mechanisms of these immunological events, ultimately 
leading to the discovery of lymphocytes as the primary culprits in acute rejection. Early 
preclinical trials demonstrated that lymphocyte-specific antibodies could be induced in 
animal models by injecting them with lymphocytes. The serum could then be isolated and 
re-injected in other animals to decrease the lymphocyte count. Thus, these experiments lead 
to the earliest forms of antilymphocyte antibody formulations, including antithymocyte 
globulin, antilymphocyte serum, and antilymphocyte globulin (Bishop et al., 1975; Cosimi et 
al., 1976). These initial medications had little specificity and broad effects, but their potent 
ability to treat acute rejection episodes led to their widespread use in the 1970’s (Cosimi, 
1981a). 
The extensive use of these formulations exposed their various drawbacks. Because of 
nonspecific binding, cross-reactivity with various hematopoietic cells revealed dose-limiting 
side effects including thrombocytopenia, anemia, and neutropenia (Henricsson et al., 1977; 
Rosenberg, 1975). Additionally, the method of preparation was not standardized, thus 
leading to dosing variations. Because these formulations were typically made in rabbits or 
horses, the proteins had potential antigenic properties leading to the development of serum 
sickness, cytokine release syndrome, or even anaphylaxis (Niblack et al., 1987; Prin Mathieu 
et al., 1997; Tatum et al., 1984).  
The development of specific, monoclonal antibodies by Kohler and Milstein circumvented 
many of the drawbacks of polyclonal formulations, including lack of specificity and 
variability in preparation (Kohler & Milstein, 1975). Muromonab, or OKT3, was the first 
monoclonal antibody prepared from mouse, which is specific for cluster of differentiation 3 
(CD3) (Cosimi et al, 1981b). OKT3 was effective at specifically depleting T cells from the 
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circulation, and became widely used as a valuable tool to combat acute rejection episodes 
(Ortho Multicenter Transplant Study Group, 1985; Ponticelli et al., 1987). Nevertheless, these 
monoclonal formulations still maintained some of the similar side effect profile of the 
polyclonal formulations, including cytokine release syndrome and human antigenic 
response to animal proteins, which lead to limited dosing in some patients (Jaffers et al., 
1986). 
The 1980’s marked an important era in transplantation with new advances in genetic 
engineering. Monoclonal antibodies became more sophisticated, targeting specific T cell 
populations and allowing blockade of T cell activation, such as the interleukin-2 receptor 
(IL-2R) or CD25 (Vincenti et al., 1997). Moreover, the ability to avoid antigenic proteins by 
encoding genetic sequences of DNA binding sites of animal proteins onto human antibodies 
led to the development of chimeric monoclonal antibodies (Boulianne et al., 1984; Jones et 
al., 1986; Morrison et al., 1984). Using these techniques, soluble fusion proteins can be 
formed by merging nonantibody receptors with the Fc portion of antibodies. 
1.2 Antibodies 
Comprehension of the structure and function of antibodies is critical to understanding the 
efficacy of antibody induction therapy. Antibodies are composed of two identical heavy 
chains (either µ, ┛, ┙, ┝, or ├) and two identical light chains (either ┢ or ┣). The heavy and 
light chain portions create two identical antigen binding sites (Fab fragment) which are held 
together by the common region, termed the Fc portion (Capra & Edmundson, 1977). The 
type of heavy chain differentiates the immunoglobulin type as IgM, IgG, IgA, IgE, and IgD. 
In clinical transplantation, the IgG molecule is typically utilized, as it’s readily produced and 
structurally feasible to manipulate with ease (Fig. 1). 
 
 
Fig. 1. Basic antibody structure. Depicted is a standard IgG molecule. The heavy chains are 
colored in blue, while the light chains are colored in green. The yellow lines signify the 
disulfide bonds 
Antibodies are present on the surface of B cells. Upon secretion into the serum, antibodies 
are able to neutralize circulating antigens. Antibodies maintain their effector functions 
irrespective of species, which make them useful in early studies of antibody therapies in 
transplantation. Antibodies are capable of various functions, including mimicking activating 
ligands of receptors and serving as receptor inhibitors by blocking the ligand binding site 
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(Tite et al., 1986; Wong et al., 1990). In some instances, antibody binding can lead to both 
activation and inhibition by inducing surface molecule internalization, whereby the 
molecule is removed from the surface of the cell (Kerr & Atkins, 1989). This results in a 
negligible net effect. A major limitation of antibody use is the inability to directly bind 
intracellular molecules. 
Antibodies have the ability to deplete target cells through two fundamental mechanisms. 
First, antibodies have the capability to activate the complement system resulting in 
complement-mediated lysis of target cells. Second, certain cells with Fc region receptors 
have the ability to phagocytose cells covered with antibodies through a mechanism termed 
antibody-dependent cellular cytotoxicity (ADCC)(Fig.2). The efficacy with which this occurs 
depends upon the Fab fragment and the Fc region (Ferrant et al., 2004). It is important to 
note that cells which have significantly matured, or memory cells, are somewhat resistant to 
antibody-dependent depletion mechanisms, possibly due to increased expression of 
antiapoptotic or complement regulatory genes (Pearl et al, 2005). 
The vast properties of antibodies make them suitable for therapeutic indications. 
Nevertheless, even minor changes in antibody structure can significantly alter function. 
Additionally, the interplay of the complement system and ADCC properties further 
complicates the predicted function of various antibody-depleting therapies. 
 
 
Fig. 2. Antibody-dependent cellular cytotoxicity (ADCC). The Fc receptor on the 
machrophage is used to bind the constant Fc portion of antibodies to facilitate engulfment of 
cells coated with antibodies 
1.3 Clinical classification of induction agents 
Induction immunosuppressive medications can be classified into two groups: depleting 
agents and non-depleting agents. The categorization is based on the ability of the 
medication to target specific antigens or cells, leading to a decrease in the total expression or 
cell count. Most depleting agents are relatively potent with potential for toxicity with 
prolonged administration. Non-depleting agents are generally well-tolerated. Depleting 
agents are also used for severe or refractory cases of acute rejection and have proven to be 
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more effective than glucocorticoids in treating episodes of acute rejection (Webster et al., 
2006). In addition, the use of induction agents has decreased the rates of acute rejection in 
the first 6 months compared to no induction therapy (Szczech et al., 1997). Although these 
short-term benefits appear promising, long-term outcomes, including patient and graft 
survival rates, have not been shown to be altered by the use of induction therapy. This is 
possibly related to the effects of long-term maintenance immunosuppressive therapy or 
patient co-morbidities. 
The overall success of a transplanted renal allograft is contingent on both surgical prowess 
and the use of potent immunosuppressive medications. Although induction therapy has not 
affected surgical morbidity, the rate of allograft thrombosis has been shown to be reduced in 
children with the use of induction agents (Humar et al., 2001; Singh et al., 1997). However, 
not all medications used are FDA-approved for induction therapy. Moreover, it is important 
to note that these medications are not without definite risks, including serious infectious 
complications and the development of post-transplant lymphoproliferative disorder (PTLD), 
which has been well-described with the use of OKT3 and maintenance immunosuppression 
(Bustami et al., 2004; Jamil et al., 1999). Because of the effects of depleting agents on T cells, 
appropriate prophylactic therapies should be administered to all transplant recipients. 
Duration of therapy is typically contingent on the donor and recipient immunological 
history. Thus, tailoring the immunosuppressive regimen to each patient is critical to 
avoiding complications.  
In 1995 induction therapy was used in less than half of all kidney transplants in the United 
States, while 10 years later, approximately 70% of all kidney transplant recipients received 
induction therapy (Meier-Kriesche et al., 2006). Given the availability of various potent, 
specific induction agents in modern transplantation, the clinical dilemma lies in selecting the 
most appropriate agent for a given patient, taking into account co-morbidities, donor 
quality, immunological status, and planned maintenance therapy. 
2. Depleting agents 
2.1 Antithymocyte globulin 
2.1.1 Mechanism 
Various polyclonal depleting agents are available; however, this discussion will focus on 
rabbit antithymocyte globulin (rATG). In rATG, the polyclonal heterologous antibody 
formulation is produced from immunizing rabbits with human thymocytes, which serve as 
the immunogens (Fig. 3) (Hardinger, 2006). The rabbit serum is then gathered and purified 
to remove antibodies with potentially detrimental effects and only the IgG isotypes are 
collected. Despite these purification techniques, it is possible that the majority of antibodies 
in these formulations serve no therapeutic purpose (Bonnefoy-Berard et al., 1991). When 
administered to humans, the rATG antibody formulations bind all antigens that the rabbits 
were exposed to during the immunization process. 
Rabbit ATG binds multiple T cell surface antigens and receptors involved in antigen 
recognition, adhesion and costimulation. These include CD2, CD3, CD4, CD5, CD8, CD28, 
CD45, and CD40L. In addition, rATG may also bind non-T cell molecules such as CD16, 
CD20, CD56, and the major histocompatibility molecules (class I and II) (Bonnefoy-Berard et 
al., 1991; Hardinger, 2006). The depleting effect of rATG occurs within 24 hours of 
administration and can persist with a prolonged serum half-life of several weeks (Bunn et 
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al., 1996; Guttmann et al., 1997). The effects of lymphocyte depletion are persists for years 
following administration, as evidenced by selectively low CD4+ T cell counts (Brennan et al., 
1999; Hardinger et al., 2004). 
 
 
Fig. 3. Polyclonal antibodies. Polyclonal antibodies are non-specific and bind multiple 
antigens as shown in the figure 
2.1.2 Applications 
Rabbit ATG has been approved for use as an induction agent and for the treatment of acute 
rejection in Europe since 1984 (IMTIX-SangStat, 2003). However, in the United States, rATG 
is indicated only for the treatment of acute rejection (as of 1998). Nevertheless, it is routinely 
administered as induction therapy in many centers in the United States. Early studies 
demonstrated an increased risk of infectious complications and post-transplant malignancy 
when administered in conjunction with cyclosporine (Merion et al., 1984). With a better 
understanding of PTLD, improved infectious prophylaxis protocols, and experience using 
lower doses of rATG, the use of rATG as an induction agent has increased. 
The most effective use of rATG depends on timing of administration. Ideally, the first dose 
should be given before the vascular anastomosis at the time of transplantation (typical dose 
1.5mg/kg/dose for a total of 4.5 to 7.5 mg/kg). This may minimize ischemia-reperfusion 
injury and potentially prevent the development of delayed graft function (Shoskes & 
Halloran, 1996). Delayed graft function is known to portend poorer outcomes in kidney 
transplant recipients, thus rATG has been used in patients at higher risk of developing this 
delayed graft function, including recipients of donation after cardiac death donors, and 
recipients of extended criteria donors (Beiras-Fernandez et al., 2006; Cecka et al., 1993; 
Shield et al., 1997). It is also administered in patients at higher risk of developing acute 
rejection in the perioperative period, such as retransplants and patients who may have 
prolonged avoidance of calcineurin inhibitors as well as to minimize maintenance therapies 
such as facilitating early corticosteroid withdrawl (Schaffer et al., 2003; Shield et al., 1997). 
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The use of rATG to treat severe or refractory acute cellular rejection episodes has been well-
established. Refractory acute cellular rejection is defined as failure to respond to 3 
consecutive days of bolus methylprednisolone (i.e. 500 mg per day) treatment. rATG is 
superior to glucocorticoids in treating acute cellular rejection episodes. Compared to other 
polyclonal antibody formulations, rATG has proven to be superior in reversing steroid-
resistant rejection and prolonging rejection-free events (Gaber et al., 1998). Patient or graft 
survival, however, have not been shown to be affected. Given the potency of rATG, it is 
typically used as supplemental agent to corticosteroids for the treatment of severe or 
refractory episodes of acute rejection. Additionally, recurrent episodes of acute rejection 
may be treated with multiple courses of rATG as long as preformed antirabbit antibodies 
are not present (Bock et al., 1995). 
2.1.3 Adverse effects 
Patients treated with rATG may experience a variety of side effects. It has been associated 
with a phenomenon called cytokine release syndrome (Fig. 4), which is common to many 
polyclonal antibody formulations. Patients may experience mild flu-like symptoms, such as 
fever, chills, nausea, urticaria, rash, and headache (Guttmann et al., 1997). This occurs as a 
result of increased production of tumor necrosis factor-┙, IL-1, and IL-6 from antibody 
binding to cell surface receptors and ensuing cell lysis (Debets et al., 1989; Guttmann et al., 
1997; Hardinger, 2006). Premedication with corticosteroids, antipyretics, and antihistamines 
can prevent and/or treat the flu-like symptoms that can occur in a subset of kidney 
transplant recipients. In some cases, patients may develop more severe shock-like reactions, 
such as dyspnea, severe hypotension, pulmonary edema, or even anaphylaxis. Although 
patients frequently experience the mild flu-like symptoms and not the more severe 
reactions, recipient co-morbid conditions, such as cardiac or pulmonary disease, should be 
considered when selecting rATG as an induction agent. Serum sickness has also been 
associated with rATG administration in up to 7-10% of patients (Buchler et al., 2003; Mourad 
et al., 2001). 
 
 
Fig. 4. Antibody activation and cytokine release. Antibodies can bind antigens resulting in 
activation of the cell and cytokine release as illustrated in the figure 
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Hematological adverse events may occur, including leucopenia and thrombocytopenia. It is 
important to monitor white blood cell, lymphocyte, and platelet counts for patients 
receiving rATG. Not surprisingly, these events may lead to an increase in infectious 
complications, including cytomegalovirus (CMV), herpes simplex virus, Epstein-Barr virus 
(EBV), and varicella (Abott et al., 2002; Gourishankar et al., 2004). 
2.2 Muromonab (OKT3) 
2.2.1 Mechanism 
Muromonab, or OKT3, is a monoclonal antibody. It is an IgG2 mouse antibody known to 
bind the epsilon component of human CD3. The CD3 complex is a T cell receptor 
intimately involved in T cell signaling and activation via a calcineurin-dependent 
pathway (Ortho Multicenter Transplant Study Group, 1985). Once the antibody binds the 
target cell, complement is activated leading to cell lysis and ADCC (Vallhonrat et al., 
1999). By this method, most T cells are effectively removed from the peripheral 
circulation. However, the T cell binding also results in T cell activation before clearance, 
leading to systemic cytokine release. When OKT3 binds the T cell receptor, the CD3 
complex is internalized (Fig. 5) to prevent further activation by persistent antigen 
presence (Chatenoud et al., 1990). Effectively, T cells that fail to be cleared are unable to be 
activated by the CD3 complex. 
 
 
Fig. 5. Internalization of an antibody. This figure is an example of internalization of the 
antigen-antibody complex after activation to prevent further stimulation by persistently low 
level of antibody in the peripheral circulation (i.e. OKT3 binding) 
2.2.2 Applications 
Early studies demonstrated the efficacy of OKT3 as an induction agent in kidney 
transplantation in conjunction with maintenance immunosuppression (Debure et al., 1988; 
Norman et al., 1988; Vigeral et al., 1986). Efficacy relies on serum availability, thus once 
administration of OKT3 ceases, maintenance immunosuppressive therapy is required. 
Typical dosing is 5 to 10 mg/dose through a peripheral or central line. Premedication with 
methylprednisolone, acetaminophen, and diphenhydramine can significantly lower the 
amount of cytokine release associated with first infusion (Chatenoud et al., 1991). 
Additionally, slower administration rates are helpful in blunting the cytokine response. 
Dosing can be continued for up to 14 days for a total dose of 70 mg. Patients with 
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significant sensitization have especially benefitted from OKT3 (Opelz, 1995). In addition, 
recipients of renal allografts experiencing delayed graft function benefit from OKT3 
infusion, as calcineurin inhibitor therapy can be delayed, avoiding added renal toxicity 
(Benvenisty et al., 1990).  
Early studies of OKT3 demonstrated a reduction in acute rejection rates and time to first 
rejection episodes; however, overall patient and graft survival rates were not changed 
(Henry et al., 2001; Norman et al., 1993). Its use has been linked to various infectious and 
malignant morbidities. Aseptic meningitis has also been linked to its use (Martin et al., 
2002). Moreover, PTLD rates are significantly increased, especially in EBV negative 
recipients receiving EBV positive allografts (Thistlethwaite et al., 1988; Cherikh et al., 2003). 
The significant side effect profile and immunogenicity of OKT3 has lead to a decline in its 
use as an induction agent.  
OKT3 remains an effective treatment for severe episodes of acute cellular rejection, or those 
refractory to steroid therapy and rATG. In the majority of cases of vigorous rejection, OKT3 
has proven efficacious (Cosimi et al., 1981b; Ortho Multicenter Transplant Study Group, 
1985; Thistlethwaite et al., 1987). The efficacy of OKT3 is maintained even if prior 
lymphocyte depleting agents have been used (Ponticelli et al., 1987). However, timing of 
therapy is important, as a delay in treatment following the 3 days of high-dose 
methylprednisolone therapy for steroid-resistant acute rejection is associated with decreased 
success (Tesi et al., 1993). OKT3 has also been used to treat vascular rejection episodes (Banff 
grade 2 or 3) (Kamath et al., 1997). 
2.2.3 Adverse effects 
As a monoclonal antibody, OKT3 selectively targets T cells, avoiding the leucopenia and 
thrombocytopenia associated with rATG. Similar to rATG, OKT3 is associated with cytokine 
release syndrome. With respect to OKT3, this is more pronounced, especially with the first 
dose as the T cells may be in a more activated state (i.e. acute cellular rejection). The 
cytokine release syndrome with OKT3 results in severe flu-like symptoms, including fever, 
chills, malaise, nausea, vomiting, and even rigors (Thistlethwaite et al., 1988). As vascular 
permeability increases, patients may experience pulmonary edema, hypotension, and 
volume overload. If there is renal dysfunction present, patients should undergo 
hemodialysis prior to first infusion to avoid volume-related complications. Patients should 
be closely monitored, especially during the initial infusions for cardiac or pulmonary 
complications. 
The utilization of OKT3 is clearly associated with antimouse antibodies in at least 30% of 
patients, depending on the immunosuppression regimens used at the time (Colvin & 
Preffer, 1991; Schroeder et al., 1990). The antibodies form against the mouse IgG molecule. If 
there is antibody formation, OKT3 is typically not reused, although higher doses may 
overcome this. This can be documented by laboratory evidence of antimouse antibody 
(Chatenoud et al., 1986; Legendre et al., 1992). 
2.3 Alemtuzumab 
2.3.1 Mechanism 
Alemtuzumab, or Campath-1H, is a monoclonal antibody to rat antihuman CD52 (Fig. 6). It 
is an IgG1 humanized molecule (Hale et al., 1986). CD52 is present in high abundance on 
most lymphocytes, including T cell, B cells, and monocytes, but not hematopoietic 
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precursors (Hale, 2001). It effectively depletes T cells, and some B cells and monocytes in the 
circulation as well as the allograft (Kirk et al., 2003). 
 
 
Fig. 6. Monoclonal antibodies. Monoclonal antibodies are specific and bind a single antigen 
as shown in the figure 
2.3.2 Applications 
Alemtuzumab has not been approved for use as an induction agent; however, this is a 
common off-label use. Currently, it is only approved to treat lymphogenous malignancies. 
As an off-label induction agent, it’s been used with various immunosuppression regimens, 
including steroid-sparing regimens. Effectively, it depletes lymphocytes at the time of 
transplantation and last for several months to a year before the immune system is 
reconstituted (Gabardi et al., 2011). Alemtuzumab is given at a dose of 30 mg or 0.3 mg/kg 
through a peripheral line over 3 hours. Sometimes 2 doses are given, although T cells are 
expectedly removed within 1 hour of initial administration (Kirk et al., 2003; Pearl et al., 
2005).  
Alemtuzumab depletes all T cell subsets, but has a predilection for more naïve T cells (Pearl 
et al., 2005). Memory T cell subsets may not be depleted with this therapy, but these cell 
types are especially susceptible to calcineurin inhibitors. Because of the prompt and intense 
depletion, alemtuzumab is especially appealing to use in patients with delayed graft 
function, as calcineurin inhibitor therapy can be withheld to avoid concomitant calcineurin-
induced renal insults. 
Early studies of alemtuzumab demonstrated its efficacy as a treatment therapy for acute 
rejection; however, it was associated with significant infectious morbidity and mortality 
(Hale et al., 1986). Patients were significantly over-immunosuppressed, especially on a triple 
maintenance therapy. More recent literature has been small studies or anecdotal data 
(Clatworthy et al., 2009; Csapo et al., 2005; Jirasiritham et al., 2010). Because its efficacy is 
greatest against naïve T cells, its use in sensitized patients may-be limited.  
In a recent study, alemtuzumab was prospectively compared to basiliximab and rATG as an 
induction agent in patients on a steroid-sparing immunosuppressive regimen (Hanaway et 
al., 2011). Alemtuzumab demonstrated lower short-term rates of acute rejection compared to 
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basiliximab in patients at low-risk of developing acute rejection. At 3-years, however, the rates 
of acute rejection were no different between alemtuzumab and rATG. Additionally, patients 
receiving alemtuzumab did not experience an increased incidence of adverse events. 
2.3.3 Adverse effects 
Similar to other depleting agents (rATG and OKT3), alemtuzumab is also associated with 
cytokine release syndrome, albeit to a lesser extent. If properly premedicated with 
methylprednisolone, acetaminophen, and diphenhydramine, the cytokine release is blunted. 
Urticaria and rash manifestations are common, while anaphylaxis and hypotension have 
also been reported. It has not been associated with antibody formation, as in the case of 
OKT3. It has been linked to the development of autoimmune thyroiditis in patients treated 
with alemtuzumab for multiple sclerosis (Coles et al., 1999). This has also been reported in a 
renal transplant recipient treated with alemetuzumab (Kirk et al., 2006). 
3. Non-depleting agents 
3.1 Basiliximab 
3.1.1 Mechanism 
Basiliximab is a chimeric mouse-human monoclonal IgG1 antibody to CD25. CD25 is the ┙-
subunit of the IL-2 receptor, which is a binding site of IL-2. Basiliximab inhibition of IL-2 
binding occurs through steric hindrance (Fig.7). In this case, the effect is not depletional, but 
rather, preventative of early T cell activation (Gabardi et al., 2011).  
 
 
Fig. 7. Antibody blockade. In this figure the antibody functions by blocking the antigen from 
binding to the receptor 
3.1.2 Applications 
Basiliximab’s biological bias for naïve T cells has limited its role to an induction agent. One 
dose is typically administered on the day of transplant as well as one dose on postoperative 
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day 4 (20 mg per dose) through a peripheral line. Its use has been associated with decreased 
rates of acute cellular rejection compared to no formal induction agent (besides 
methylprednisolone) on triple or double drug immunosuppression regimens (Kahan et al., 
1999; Nashan et al., 1997). Additional studies comparing basiliximab induction to polyclonal 
antibody depleting induction agents in the setting of triple maintenance 
immunosuppression regimens have shown similar outcomes, including acute rejection 
rates and delayed graft function (Lebranchu et al., 2002; Mourad et al., 2004). Basiliximab 
induction has also been used in steroid avoidance immunosuppression regimens (Afaneh 
et al., 2010). In the setting of monotherapy or calcineurin inhibitor free regimens, 
basiliximab has not been shown to be useful (Parrott et al., 2005; Vincenti et al., 2001). In 
some instances of excellent allograft human leukocyte antigen (HLA)-matching (i.e. 2-
haplotype matches), it’s been used as an effective induction agent with steroid-sparing 
immunosuppressive regimens (Afaneh et al., 2010). Given the relatively mild side effect 
profile, basiliximab is well-tolerated in all patients, even those with significant cardiac or 
pulmonary co-morbidities. It has no role in the treatment of acute rejection episodes as a 
rescue agent. 
3.1.3 Adverse effects 
Because of the mechanism of action of basiliximab, the side effect profile is relatively mild 
(Kahan et al., 1999; Nashan et al., 1997). Cytokine release syndrome does not occur, as T cells 
are not activated or stimulated. The most serious adverse event is hypersensitivity, which is 
rare (<1%)(Gabardi et al., 2011). There is no increased risk of infectious complications or 
PTLD compared to no induction therapy (Cherikh et al., 2003). 
3.2 Daclizumab 
3.2.1 Mechanism 
Similar to basiliximab, daclizumab is an antagonist to CD25; however, it is a humanized 
IgG1 antibody. The CD25 molecule was the first humanized monoclonal antibody to be 
successfully targeted in the field of transplantation (Kirkman et al., 1991). The mechanism of 
action of daclizumab essentially duplicates that of other IL-2 receptor antagonists. 
3.2.2 Applications 
Like basiliximab, daclizumab has been shown to decrease the incidence of acute cellular 
rejection when administered as an induction agent (Hershberger et al., 2005; Nashan et al., 
1999). Given the favorable side effect profile, it is tolerated well in recipients, irrespective of 
co-morbid conditions. The main disadvantage of daclizumab, as compared to basiliximab, is 
that it is more costly and requires repeated administrations (Gabardi et al., 2011). Because 
the demand for the medication has been relatively low, it has been discontinued by the 
manufacturer. It has no role as a rescue agent for acute rejection. 
3.2.3 Adverse effects 
The side effect profile is similar to that of basiliximab and generally favorable. Cytokine 
release is not typically associated with this agent (Hershberger et al., 2005; Nashan et al., 
1999). Like other IL-2 receptor antagonists, the risk of PTLD is not significantly increased 
with use (Cherikh et al., 2003). 
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4. Desensitizing agents 
4.1 Rituximab 
4.1.1 Mechanism 
Rituximab is a monoclonal chimeric antibody to the CD20 molecule. CD20 is a glycoprotein 
on the cell surface of circulating, mature B cells. Rituximab effectively depletes CD20+ cells 
from the circulation by inducing apoptosis (Deans et al., 2002). These cells are precursors to 
antibody-producing plasma cells, and their role in transplantation is only partially 
characterized. They may play a role in acute rejection, as B cells can act as antigen-
presenting cells. 
4.1.2 Applications 
Rituximab is approved for use in various lymphomas, leukemias, PTLD, and rheumatoid 
arthritis (Gabardi et al., 2011; Grillo-Lopez et al., 1999). Peripheral veins can be used for 
administration and dosing is dependent on the indication. A recent study examining the 
role of rituximab as an induction agent found no benefit compared to placebo (Tyden et al., 
2009). However, it does play a role as a desensitizing agent in patients with preformed 
donor specific antibodies (DSA), in conjunction with total plasmapheresis and/or 
intravenous immunoglobulin (IVIG)(Fuchinoue et al., 2011; Sonnenday et al., 2004). 
Additionally, it has been used to aid in transplanting across blood group barriers in donor 
recipient pairs and in patients with positive crossmatches following antibody elimination. 
Rituximab is increasingly being used to treat episodes of vascular rejection and antibody-
mediated rejections (Y.T. Becker et al., 2006; Fehr et al., 2009). Finally, rituximab is a proven 
and effective agent in the treatment of PTLD (Svoboda et al., 2006). Administration does not 
replace immunosuppression reduction or chemotherapy, but rather supplements the other 
modalities. 
4.1.3 Adverse effects 
Rituximab is generally well-tolerated with minimal side effects. Anaphylaxis remains a 
theoretical concern, as is the case with most agents. Reports on infectious complications 
related to rituximab have been variable (Grim et al., 2007; Kamar et al., 2010; Nishida et al., 
2009). In some instances there was no difference in bacterial, viral, or fungal infections in 
kidney transplant recipients treated with rituximab, however, this remains controversial. 
4.2 Bortezomib 
4.2.1 Mechanism 
Bortezomib is a proteasomal inhibitor that causes apoptosis of plasma cells. It binds the 26S 
subunit of the proteasome (Bonvini et al., 2007). Proteasome inhibition ultimately leads to 
apoptosis during mitosis. Bortezomib selectively causes apoptosis in CD138+ plasma cells 
(Perry et al., 2009). Additionally, Bortezomib may block T cell cycling and decrease the number 
of circulating B cells by reducing bone marrow levels of IL-6 (San Miguel et al., 2008). 
4.2.2 Applications 
Bortezomib has not been approved for use in kidney transplantation; however, it has been 
used in sensitized patients (Perry et al., 2009). Bortezomib has been successfully used to 
decrease DSA levels, which may play a role in acute antibody-mediated rejection (AMR) 
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(Trivedi et al., 2009). Furthermore, in vivo data has demonstrated a decrease in the 
percentage of bone marrow plasma cells, antibody production, and allospecificities of 
plasma cells in bone marrow aspirates of patients treated with bortezomib i in the setting of 
AMR (Perry et al., 2009).  
4.2.3 Adverse events 
Bortezomib has been associated with various side effects. Although gastrointestinal side 
effects are the most common, peripheral neuropathy has also been reported, especially in 
patients with a pre-existing history of neuropathy (Bonvini et al., 2007). Moreover, 
myelosuppression and shingles has been reported. 
4.3 Intravenous Immunoglobulin (IVIG) 
4.3.1 Mechanism 
Intravenous immunoglobulin, or IVIG, is pooled polyclonal antibodies from different 
human donors. These are high-dose human IgG fractions with a wide range of specificities. 
These are non-T cell specific formulations and have no specific cell targets (Jordan et al., 
2011). It is able to bind activated complement components or even inhibit complement 
activation (Jordan et al., 2009). IVIG may also modulate the alloimmune response by binding 
to the Fc receptor of antigen-presenting cells, effectively quelling the alloimmune response 
(Kazatchkine & Kaveri, 2001). 
4.3.2 Applications 
Despite the inability to deplete T cells, IVIG is an effective treatment of acute cellular 
rejection. Early studies showed that IVIG was as effective as OKT3 in reversing steroid-
resistant acute rejection episodes (Casadei et al., 2001). In the setting of antibody-mediated 
rejection, IVIG has been shown to be beneficial when used in conjunction with 
plasmapheresis and/or rituximab (Lefaucher et al., 2009; Shehata et al., 2010). As a 
desensitization agent alone, no study has demonstrated a clear benefit (Pisani et al., 1999; 
Shehata et al., 2010). Definitive reduction of antibody was not shown and a survival 
advantage was not evident. 
4.3.3 Adverse effects 
The side-effect profile of IVIG increases with dosing. High-dose IVIG is associated with 
more infusion-related complications, such as headache, thrombotic incidents, hemolysis, 
bronchospasms, osmotic nephropathy, or even aseptic meningitis (Jordan et al., 2011; 
Kahwaji et al., 2009). Sucrose-based and high osmolality products have a higher risk of 
developing osmotic nephropathy as opposed to other preparation. Nevertheless, it is 
typically well-tolerated, especially at lower doses and most patients report only headache. 
5. Experimental agents 
5.1 Siplizumab (MEDI-507) 
Originally described as BTI-322, siplizumab is a monoclonal humanized antibody to CD2. It 
is an IgG1k molecule derived from rat (Pruett et al., 2009). CD2, or lymphocyte function-
associated antigen-2 (LFA-2), is an important T cell adhesion molecule that binds to CD58, 
or LFA-3. This is a transmembrane signal transduction molecule that facilitates T cell 
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receptor binding. Early studies examined the use of siplizumab as an induction agent and 
treatment modality for acute rejection in solid organ transplantation as well as graft-versus-
host disease (Pruett et al., 2009; Squifflet et al., 1997). The first human study of siplizumab 
demonstrated the safety and feasibility in kidney transplantation, as compared to placebo; 
however, current endeavors are focused on investigating its use in nonmyeloablative 
conditioning regimens to achieve mixed chimerism (Kawai et al., 2008; Pruett et al., 2009; 
Spitzer et al., 2003). In addition, it is being investigated for the treatment of plaque psoriasis 
(Langley et al., 2010). 
5.2 Alefacept 
Alefaept is a dimeric fusion protein (Fig.8) constituted from LFA-3 and the human Fc 
portion of IgG1. Studies have demonstrated inhibition of T cell proliferation and depletion 
of effector memory T cells (Ellis & Krueger, 2001; Gordon et al., 2003). Currently, alefacept is 
approved to treat plaque psoriasis. Preclinical studies in nonhuman primates have 
demonstrated a survival benefit of alefacept, when used in conjunction with costimulatory 
blockade, but not alone; however in human trials have never shown a benefit (Weaver et al., 
2009). 
 
 
Fig. 8. Mimicry. In this figure, the antibody is fused with a protein structural similar to the 
intended antigen, which can serve as activating or inhibitory 
5.3 Costimulatory blockade 
5.3.1 Abatacept 
Abatacept is a recombinant cytotoxic T-lymphocyte antigen 4 (CTLA4) fused with the Fc 
portion of IgG1 (Lenschow et al., 1992; Turka et al., 1992). Animal models demonstrated its 
ability to delay or even prevent the onset of allograft rejection, which is comparable to 
basiliximab and some polyclonal antibody therapies (Kirk et al., 1997; Lenschow et al., 1992; 
Turka et al., 1992). It has been approved for treatment of rheumatoid arthiritis (Genovese et 
al., 2005; Nogid & Pham, 2006). Further investigations of this medication are not currently 
under development. 
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5.3.2 Belatacept 
Belatacept is the improved version of abatacept, providing selective blockade of T cell 
activation as a fusion protein. Two amino acids have been changed to improve dissociation 
rates when binding to CD80 and CD86 (Vincenti et al., 2005, 2010). In the phase II trial 
comparing belatacept to cyclosporine, acute rejection rates were similar, while allograft 
function was significantly improved in patients receiving belatacept (Vincenti et al., 2005). In 
the phase III trial of kidney transplantation, patients receiving belatacept experienced 
improved allograft function at 12 months; however, acute rejection rates and severity of 
acute rejection episodes were significantly higher in the belatacept arm of the study. 
Additionally, the incidence of PTLD was greater in patients receiving belatacept (Vincenti et 
al., 2010). An additional study investigating the efficacy of belatacept in kidney 
transplantation of extended criteria donors demonstrated similar results, with a predilection 
towards central nervous system (CNS) forms of PTLD (Durrbach et al., 2010). The novelty of 
costimulation blockade is the ability to avoid calcineurin inhibitors, especially in allografts 
at increased risk of delayed graft function. Belatacept has recently been approved for the 
prophylaxis of organ rejection in adult patients receiving a kidney transplant, in 
combination with basiliximab induction, mycophenolate mofetil, and corticosteroids 
(Bristol-Myers Squibb Company 2011). Current recommendations include using it only in 
patients who are EBV seropositive; however, patients should be monitored for an increased 
risk of infectious complications and Progressive Multifocal Leukoencephalopathy. 
5.3.3 CD7 antagonism 
SDZCHH380 is a monoclonal antibody targeting CD7. This IgG1 chimeric mouse antibody 
was initially studied in kidney transplantation (Lazarovits et al., 1993; Sharma et al., 1997). 
The CD7 molecule is expressed on T cells and natural killer cells during early 
differentiation, functioning as a costimulatory molecule. Early studies of SDZCHH380 as an 
induction agent in kidney transplantation demonstrated comparable short and long-term 
outcomes to OKT3 induction (Sharma et al., 1997). Despite favorable results up to 4 years 
following administration, further investigative endeavors were not pursued in solid organ 
transplantation. 
5.3.4 T cell receptor antagonism 
T10B9, or Medi-500, is a monoclonal antibody to the T cell receptor. Specifically, this is a 
murine IgM┢ molecule to the ┙┚ heterodimer region of the CD3 complex (Brown et al., 1996; 
Waid et al., 1992, 2009). Because it does not bind directly to the Fc receptor, there is reduced 
immune stimulation and occurrence of cytokine release syndrome. The end result is T cell 
depletion. Early studies demonstrated the efficacy of this agent as induction therapy and a 
treatment modality for acute rejection in solid organ transplantation, as compared to OKT3 
(Waid et al., 1997a, 1997b). However, given the efficacy of similar humanized monoclonal 
antibodies, further investigations in solid organ transplantation were not pursued. 
6. Special considerations 
6.1 High risk donor kidneys & recipients 
Marginal donor kidneys are defined as expanded criteria donors (ECD) or donation after 
cardiac death donors (DCD). These allografts are at higher risk of developing delayed graft 
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function, which has been shown to decrease overall allograft survival and increase the 
incidence of acute rejection (Deroure et al., 2010; Rudich et al., 2002). There was a large 
prospective, international, randomized controlled trial examining the efficacy of rATG 
versus basiliximab in patients at high risk of delayed graft function (Brennan et al., 2006). 
Patients were maintained on a cyclosporine-based triple drug immunosuppression regimen 
and eligibility criteria included ECD or DCD allografts, standard criteria donors (SCD) with 
greater than 24 hours of cold ischemia time, repeat transplants, panel-reactive antibody 
value exceeding 20% before transplantation, donors with acute tubular necrosis (ATN), 
recipient black race, or one or more HLA mismatches. The incidence of delayed graft 
function was not significantly different between patients receiving rATG and basiliximab 
induction. However, the incidence of biopsy-proven acute rejection was significantly lower 
in patients receiving rATG. Additionally, severe rejection episodes requiring antibody 
therapy were less frequent in the rATG group. Interestingly, the overall incidence of 
infection was significantly lower in the basiliximab group, yet the incidence of CMV was 
lower in the rATG group. 
6.2 Sensitization & incompatibility 
Sensitization to HLA antigen typically occurs as a result of blood transfusions, pregnancy, 
or previous transplantation (Marfo et al., 2011). These patients are more likely develop 
circulating DSA and have a positive cross-match during transplantation evaluation. 
Sensitized patients wait considerable longer on the deceased donor waitlist.  
Various modalities have been developed to combat sensitization. Antibodies can be 
removed by plasmapheresis and immunoadsorption techniques; however anti-HLA 
antibodies generally rebound and return to baseline (Hakim et al., 1990). As discussed 
earlier, rituximab has also been used with varying success, as B cells recovery occurs 6 to 12 
months following administration. Bortezomib has been used in sensitized patients (Perry et 
al., 2009). Recently, a new medication called eculizumab has emerged as a humanized 
monoclonal antibody to complement component 5 (C5) to mediate complement-mediated 
injury, which may have potential in desensitization protocols (Larrea et al., 2010). IVIG has 
also been used in sensitized patients to acutely decrease PRA levels, especially in ABO-
incompatible patients. Finally, splenectomy has also been used in desensitization protocols 
of ABO-incompatible patients (Kaplan et al., 2007). 
Despite these numerous combinations of these therapies with acceptable short-term 
outcomes, intermediate-term outcomes have been modest at best. Some have reported graft 
survival rates at 3 years to be 78% (Haririan et al., 2009) and 4-year graft survival of only 
66% (Lefaucher et al., 2007). Additionally, higher rates of clinical and subclinical antibody-
mediated rejection have been reported (Haas et al, 2007; Loupy et al., 2009). 
6.3 Older recipients 
Several considerations should be examined when choosing induction therapy in older 
recipients. Older patients may have lower rates of acute rejection as a result of diminished 
immune activity (B.N. Becker 1996; Friedman et al., 2004). There is also a higher rate of 
infectious complications as well as malignancies (Meier-Kriesche et al., 2001; Stratta et al., 
2008). Thus, less intense induction and immunosuppression appear sufficient. However, if 
significant HLA-mismatch is present, higher rates of acute rejection have been described 
(Frei et al., 2008; Fritsche et al., 2003; Giessing et al., 2003). Nevertheless, the safety profile of 
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IL-2 receptor antibodies in patients with considerable comorbidities, such as the older 
recipients, may be preferred. 
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